Isogenica appoints Dr Emma Sceats as Chief Executive Officer
Isogenica Ltd, a leader in the design and construction of diverse, fully synthetic, antibody libraries for biopharmaceutical discovery, today announced that Dr Emma Sceats has been appointed Chief Executive Officer and will join Isogenica’s Board of Directors with immediate effect.
Before joining Isogenica, Dr Sceats, was CEO of CN Bio Innovations, which she grew from a Oxford University spin-out to a recognised leader in Organ-on-Chip technologies. Dr Sceats was instrumental in the development and execution of CN Bio’s vision, resulting in strong revenue growth, rapid development of two innovative new products, and a pioneering partnership with the Food and Drug Administration to characterise the use of Organs-on-Chips in drug development and regulatory evaluation.
Commenting on the announcement, Jan-Olof Lundin, Chairman of Isogenica, said: “Since reaffirming its commitment to biopharmaceutical discovery technologies with further investments in single-domain antibody libraries (llamdA®) and fully synthetic, highly diverse human Fab fragment antibody libraries (Alexandria), the company has signed multiple licence agreements providing pharmaceutical and biotech partners with next generation biopharmaceutical technology platforms. The Board and I are confident that Emma is the right person to build on this momentum, bringing her experience and fresh perspectives to reinforce and extend the company’s existing strengths.”
“I’ve been impressed by the company’s consistent record of delivering high-quality biotherapeutic candidates to its licensees, and the commitment to innovation such as novel, high-diversity antibody libraries and the development of an high-throughput in vitro display system. I am honoured to accept this appointment and excited to join the Isogenica team to deliver the next phase of innovation and growth.” said Dr Sceats.
Isogenica is developing LlamdA® (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process. Over the last four years
Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”
T +44 1799 533 680